Inherited Disorders of Renal Salt Homeostasis: Insights from Molecular Genetics Studies

Seldin and Geibisch's The Kidney

Volumn 1, Issue , 2013, Pages 1213-1240

  Scholl, Ute I ^a   Lifton, Richard P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884056732     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381462-3.00036-7     Document Type: Chapter

References (207)

1. Lifton R.P., Gharavi A.G., Geller D.S. Molecular mechanisms of human hypertension. Cell 2001, 104:545-556.
2. Montani J.P., Mizelle H.L., Adair T.H., Guyton A.C. Regulation of cardiac output during aldosterone-induced hypertension. J Hypertens Suppl 1989, 7:S206-S207.
3. Sutherland D.J., Ruse J.L., Laidlaw J.C. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966, 95:1109-1119.
4. Litchfield W.R., Anderson B.F., Weiss R.J., Lifton R.P., Dluhy R.G. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998, 31:445-450.
5. Rich G.M., Ulick S., Cook S., Wang J.Z., Lifton R.P., Dluhy R.G. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 1992, 116:813-820.
6. Litchfield W.R., Coolidge C., Silva P., Lifton R.P., Fallo F., Williams G.H., et al. Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997, 82:1507-1510.
7. Chu M.D., Ulick S. Isolation and identification of 18-hydroxycortisol from the urine of patients with primary aldosteronism. J Biol Chem 1982, 257:2218-2224.
8. Ulick S., Chu M.D., Land M. Biosynthesis of 18-oxocortisol by aldosterone-producing adrenal tissue. J Biol Chem 1983, 258:5498-5502.
9. Lifton R.P., Dluhy R.G., Powers M., Rich G.M., Cook S., Ulick S., et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
10. Lifton R.P., Dluhy R.G., Powers M., Rich G.M., Gutkin M., Fallo F., et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992, 2:66-74.
11. Pilon C., Mulatero P., Barzon L., Veglio F., Garrone C., Boscaro M., et al. Mutations in CYP11B1 gene converting 11beta-hydroxylase into an aldosterone-producing enzyme are not present in aldosterone-producing adenomas. J Clin Endocrinol Metab 1999, 84:4228-4231.
12. Jonsson J.R., Klemm S.A., Tunny T.J., Stowasser M., Gordon R.D. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995, 207:565-571.
13. Funder J.W., Carey R.M., Fardella C., Gomez-Sanchez C.E., Mantero F., Stowasser M., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3266-3281.
14. Fallo F., Pilon C., Williams T.A., Sonino N., Morra Di Cella S., Veglio F., et al. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. J Hum Hypertens 2004, 18:47-51.
15. Ehret G.B., Munroe P.B., Rice K.M., Bochud M., Johnson A.D., Chasman D.I., et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011, 478:103-109.
16. Conn J.W., Louis L.H. Primary aldosteronism: a new clinical entity. Trans Assoc Am Physicians 1955, 68:215-231. discussion, 231-213.
17. Rossi G.P., Bernini G., Caliumi C., Desideri G., Fabris B., Ferri C., et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293-2300.
18. + channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011, 331:768-772.
19. + channel signature sequence. Biophys J 1994, 66:1061-1067.
20. + channel Kir2.2 at 3.1 Å resolution. Science 2009, 326:1668-1674.
21. + channel in adrenocortical cells is TREK-1. J Biol Chem 2002, 277:49186-49199.
22. Czirjak G., Enyedi P. TASK-3 dominates the background potassium conductance in rat adrenal glomerulosa cells. Mol Endocrinol 2002, 16:621-629.
23. + conductance in rat adrenal glomerulosa cells. J Membr Biol 1997, 156:261-277.
24. Brauneis U., Vassilev P.M., Quinn S.J., Williams G.H., Tillotson D.L. ANG II blocks potassium currents in zona glomerulosa cells from rat, bovine, and human adrenals. Am J Physiol 1991, 260:E772-E779.
25. Hu C., Rusin C.G., Tan Z., Guagliardo N.A., Barrett P.Q. Zona glomerulosa cells of the mouse adrenal cortex are intrinsic electrical oscillators. J Clin Invest 2012, 122(6):2046-2053.
26. Spat A., Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004, 84:489-539.
27. Akerström T, Crona J, Delgado Verdugo A, Starker LF, Cupisti K, Willenberg HS, et al. Comprehensive Re-Sequencing of Adrenal Aldosterone Producing Lesions Reveal Three Somatic Mutations near the KCNJ5 Potassium Channel Selectivity Filter. PLoS One 2012;7:e41926.
28. Boulkroun S., Beuschlein F., Rossi G.P., Golib-Dzib J.F., Fischer E., Amar L., et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012, 59:592-598.
29. Geller D.S., Zhang J., Wisgerhof M.V., Shackleton C., Kashgarian M., Lifton R.P. A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 2008, 93:3117-3123.
30. Scholl U.I., Nelson-Williams C., Yue P., Grekin R., Wyatt R.J., Dillon M.J., et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci USA 2012, 109:2533-2538.
31. Mulatero P., Tauber P., Zennaro M.C., Monticone S., Lang K., Beuschlein F., et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012, 59:235-240.
32. Mussa A., VCamilla R., Monticone S., Porta F., Tessaris D., Verna F., et al. Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism. Endocr J 2012, 59:497-502.
33. Charmandari E., Sertedaki A., Kino T., Merakou C., Hoffman D.A., Hatch M.M., et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab 2012, 97:E1532-9.
34. Pivonello R., Ferone D., de Herder W.W., de Krijger R.R., Waaijers M., Mooij D.M., et al. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab 2004, 89:4493-4502.
35. Tannin G.M., Agarwal A.K., Monder C., New M.I., White P.C. The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 1991, 266:16653-16658.
36. Zachmann M., Tassinari D., Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab 1983, 56:222-229.
37. Rosler A., Leiberman E., Sack J., Landau H., Benderly A., Moses S.W., et al. Clinical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Horm Res 1982, 16:133-141.
38. Cerame B.I., New M.I. Hormonal hypertension in children: 11beta-hydroxylase deficiency and apparent mineralocorticoid excess. J Pediatr Endocrinol Metab 2000, 13:1537-1547.
39. Portrat S., Mulatero P., Curnow K.M., Chaussain J.L., Morel Y., Pascoe L. Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11beta-hydroxylase) and CYP11B2(aldosterone synthase) cause steroid 11beta-hydroxylase deficiency and congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001, 86:3197-3201.
40. Biglieri E.G., Herron M.A., Brust N. 17-hydroxylation deficiency in man. J Clin Invest 1966, 45:1946-1954.
41. Costa-Santos M., Kater C.E., Auchus R.J. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab 2004, 89:49-60.
42. Kagimoto M., Winter J.S., Kagimoto K., Simpson E.R., Waterman M.R. Structural characterization of normal and mutant human steroid 17 alpha-hydroxylase genes: molecular basis of one example of combined 17 alpha-hydroxylase/17,20 lyase deficiency. Mol Endocrinol 1988, 2:564-570.
43. Geller D.H., Auchus R.J., Mendonca B.B., Miller W.L. The genetic and functional basis of isolated 17,20-lyase deficiency. Nat Genet 1997, 17:201-205.
44. New M.I., Levine L.S., Biglieri E.G., VPareira J., Ulick S. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977, 44:924-933.
45. Ulick S., Levine L.S., Gunczler P., Zanconato G., Ramirez L.C., Rauh W., et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979, 49:757-764.
46. Arriza J.L., Weinberger C., Cerelli G., Glaser T.M., Handelin B.L., Housman D.E., et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268-275.
47. Krozowski Z.S., Funder J.W. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 1983, 80:6056-6060.
48. Mune T., Rogerson F.M., Nikkila H., Agarwal A.K., White P.C. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 1995, 10:394-399.
49. Kotelevtsev Y., Brown R.W., Fleming S., Kenyon C., Edwards C.R., Seckl J.R., et al. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest 1999, 103:683-689.
50. Palermo M., Delitala G., Mantero F., Stewart P.M., Shackleton C.H. Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone. J Endocrinol Invest 2001, 24:17-23.
51. Knops N.B., Monnens L.A., Lenders J.W., Levtchenko E.N. Apparent mineralocorticoid excess: time of manifestation and complications despite treatment. Pediatrics 2011, 127:e1610-e1614.
52. Stewart P.M., Wallace A.M., Valentino R., Burt D., Shackleton C.H., Edwards C.R. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987, 2:821-824.
53. Geller D.S. Pseudohypoaldosteronism Type 1 and Hypertension Exacerbated in Pregnancy. Genetic diseases of the kidney. burlingon 2009, 301-312. Elsevier, London, San Diego, New York. R.P. Lifton, S. Somlo, G.H. Giebisch, D.W. Seldin (Eds.).
54. Geller D.S., Farhi A., Pinkerton N., Fradley M., Moritz M., Spitzer A., et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289:119-123.
55. Fagart J., Huyet J., Pinon G.M., Rochel M., Mayer C., Rafestin-Oblin M.E. Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol 2005, 12:554-555.
56. Liddle G.W., Bledsoe T., Coppage W.S. A familial renal disorder stimulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 1963, 76:199-213.
57. Shimkets R.A., Warnock D.G., Bositis C.M., Nelson-Williams C., Hansson J.H., Schambelan M., et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994, 79:407-414.
58. Hansson J.H., Nelson-Williams C., Suzuki H., Schild L., Shimkets R., Lu Y., et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 1995, 11:76-82.
59. + channel is made of three homologous subunits. Nature 1994, 367:463-467.
60. Canessa C.M., Merillat A.M., Rossier B.C. Membrane topology of the epithelial sodium channel in intact cells. Am J Physiol 1994, 267:C1682-C1690.
61. Hansson J.H., Schild L., Lu Y., Wilson T.A., Gautschi I., Shimkets R., et al. A de novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci USA 1995, 92:11495-11499.
62. + channel. Cell 1995, 83:969-978.
63. Schild L., Canessa C.M., Shimkets R.A., Gautschi I., Lifton R.P., Rossier B.C. A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the Xenopus laevis oocyte expression system. Proc Natl Acad Sci USA 1995, 92:5699-5703.
64. Firsov D., Schild L., Gautschi I., Merillat A.M., Schneeberger E., Rossier B.C. Cell surface expression of the epithelial Na channel and a mutant causing Liddle syndrome: a quantitative approach. Proc Natl Acad Sci USA 1996, 93:15370-15375.
65. + channel deleted in Liddle's syndrome. EMBO J 1996, 15:2371-2380.
66. + channel. FASEB J 2001, 15:204-214.
67. Hiltunen T.P., Hannila-Handelberg T., Petajaniemi N., Kantola I., Tikkanen I., Virtamo J., et al. Liddle's syndrome associated with a point mutation in the extracellular domain of the epithelial sodium channel gamma subunit. J Hypertens 2002, 20:2383-2390.
68. Botero-Velez M., Curtis J.J., Warnock D.G. Brief report: liddle's syndrome revisited - a disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994, 330:178-181.
69. Pradervand S., Wang Q., Burnier M., Beermann F., Horisberger J.D., Hummler E., et al. A mouse model for Liddle's syndrome. J Am Soc Nephrol 1999, 10:2527-2533.
70. Paver W.K., Pauline G.J. Hypertension and hyperpotassaemia without Renal disease in a young male. Med J Aust 1964, 2:305-306.
71. Farfel Z., Iaina A., Rosenthal T., Waks U., Shibolet S., Gafni J. Familial hyperpotassemia and hypertension accompanied by normal plasma aldosterone levels: possible hereditary cell membrane defect. Arch Intern Med 1978, 138:1828-1832.
72. Farfel Z., Rosenthal T., Shibolet S., Iaina A., Gafni J. Familial hyperkalemia and hypertension. Harefuah 1976, 90:468-470.
73. Lee M.R., Morgan D.B. Familial hyperkalaemia responsive to benzothiadiazine diuretic. Lancet 1980, 1:879.
74. Schambelan M., Sebastian A., Rector F.C. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption. Kidney Int 1981, 19:716-727.
75. Wilson F.H., Disse-Nicodeme S., Choate K.A., Ishikawa K., Nelson-Williams C., Desitter I., et al. Human hypertension caused by mutations in WNK kinases. Science 2001, 293:1107-1112.
76. Yang C.L., Angell J., Mitchell R., Ellison D.H. WNK kinases regulate thiazide-sensitive Na-Cl co-transport. J Clin Invest 2003, 111:1039-1045.
77. + secretion. Nat Genet 2003, 35:372-376.
78. - permeability is regulated by WNK4 kinase: insight into normal physiology and hypertension. Proc Natl Acad Sci USA 2004, 101:14877-14882.
79. Yamauchi K., Rai T., Kobayashi K., Sohara E., Suzuki T., Itoh T., et al. Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. Proc Natl Acad Sci USA 2004, 101:4690-4694.
80. Lalioti M.D., Zhang J., Volkman H.M., Kahle K.T., Hoffmann K.E., Toka H.R., et al. Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. Nat Genet 2006, 38:1124-1132.
81. Kahle K.T., Ring A.M., Lifton R.P. Molecular physiology of the WNK kinases. Annu Rev Physiol 2008, 70:329-355.
82. Hoorn E.J., Nelson J.H., McCormick J.A., Ellison D.H. The WNK kinase network regulating sodium, potassium, and blood pressure. J Am Soc Nephrol 2011, 22:605-614.
83. Kahle K.T., Wilson F.H., Lifton R.P. The Syndrome of Hypertension and Hyperkalemia (Pseudohypoaldosteronism Type II): WNK Kinases regulate the balance between renal salt reabsorption and potassium secretion. Genetic diseases of the kidney 2009, 313-329. Elsevier, Burlington, London, San Diego, New York. R.P. Lifton, S. Somlo, G. Giebisch, D.W. Seldin (Eds.).
84. Wilson F.H., Kahle K.T., Sabath E., Lalioti M.D., Rapson A.K., Hoover R.S., et al. Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl co-transporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci USA 2003, 100:680-684.
85. Subramanya A.R., Liu J., Ellison D.H., Wade J.B., Welling P.A. WNK4 diverts the thiazide-sensitive NaCl co-transporter to the lysosome and stimulates AP-3 interaction. J Biol Chem 2009, 284:18471-18480.
86. He G, Wang HR, Huang SK, Huang CL. Intersectin links WNK kinases to endocytosis of ROMK1. J Clin Invest 2007;117:1078-87.
87. + channel in vitro and in vivo. Proc Natl Acad Sci USA 2007, 104:4020-4024.
88. + homeostasis. Proc Natl Acad Sci USA 2007, 104:4025-4029.
89. Lazrak A., Liu Z., Huang C.L. Antagonistic regulation of ROMK by long and kidney-specific WNK1 isoforms. Proc Natl Acad Sci USA 2006, 103:1615-1620.
90. Xu B.E., Stippec S., Chu P.Y., Lazrak A., Li X.J., Lee B.H., et al. WNK1 activates SGK1 to regulate the epithelial sodium channel. Proc Natl Acad Sci USA 2005, 102:10315-10320.
91. Ohta A., Yang S.S., Rai T., Chiga M., Sasaki S., Uchida S. Overexpression of human WNK1 increases paracellular chloride permeability and phosphorylation of claudin-4 in MDCKII cells. Biochem Biophys Res Commun 2006, 349:804-808.
92. San-Cristobal P., Pacheco-Alvarez D., Richardson C., Ring A.M., Vazquez N., Rafiqi F.H., et al. Angiotensin II signaling increases activity of the renal Na-Cl co-transporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci USA 2009, 106:4384-4389.
93. McCormick J.A., Ellison D.H. The WNKs: atypical protein kinases with pleiotropic actions. Physiol Rev 2011, 91:177-219.
94. - co-transporter by angiotensin II is a WNK4-dependent process. Proc Natl Acad Sci USA 2012, 109:7929-7934.
95. Delaloy C., Elvira-Matelot E., Clemessy M., Zhou X.O., Imbert-Teboul M., Houot A.M., et al. Deletion of WNK1 first intron results in misregulation of both isoforms in renal and extrarenal tissues. Hypertension 2008, 52:1149-1154.
96. Boyden L.M., Choi M., Choate K.A., Nelson-Williams C.J., Farhi A., Toka H.R., et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 2012, 482:98-102.
97. Louis-Dit-Picard H., Barc J., Trujillano D., Miserey-Lenkei S., Bouatia-Naji N., Pylypenko O., et al. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet 2012, 44:456-460.
98. Peter M., Fawaz L., Drop S.L., Visser H.K., Sippell W.G. Hereditary defect in biosynthesis of aldosterone: aldosterone synthase deficiency 1964-1997. J Clin Endocrinol Metab 1997, 82:3525-3528.
99. Ulick S., Gautier E., Vetter K.K., Markello J.R., Yaffe S., Lowe C.U. An aldosterone biosynthetic defect in a salt-losing disorder. J Clin Endocrinol Metab 1964, 24:669-672.
100. Pascoe L., Curnow K.M., Slutsker L., Rosler A., White P.C. Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci USA 1992, 89:4996-5000.
101. Mitsuuchi Y., Kawamoto T., Miyahara K., Ulick S., Morton D.H., Naiki Y., et al. Congenitally defective aldosterone biosynthesis in humans: inactivation of the P-450C18 gene (CYP11B2) due to nucleotide deletion in CMO I deficient patients. Biochem Biophys Res Commun 1993, 190:864-869.
102. Kayes-Wandover K.M., Tannin G.M., Shulman D., Peled D., Jones K.L., Karaviti L., et al. Congenital hyperreninemic hypoaldosteronism unlinked to the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 2001, 86:5379-5382.
103. White P.C., New M.I., Dupont B. HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci USA 1984, 81:7505-7509.
104. Bongiovanni A.M., Root A.W. The adrenogenital syndrome. N Engl J Med 1963, 268:1283-1289. contd.
105. Higashi Y., Yoshioka H., Yamane M., Gotoh O., Fujii-Kuriyama Y. Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene. Proc Natl Acad Sci USA 1986, 83:2841-2845.
106. Speiser P.W., Azziz R., Baskin L.S., Ghizzoni L., Hensle T.W., Merke D.P., et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95:4133-4160.
107. Rheaume E., Simard J., Morel Y., Mebarki F., Zachmann M., Forest M.G., et al. Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene. Nat Genet 1992, 1:239-245.
108. Lin D, Sugawara T, Strauss JF 3rd, Clark BJ, Stocco DM, Saenger P, et al. Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 1995; 267:1828-31.
109. Cheek D.B., Perry J.W. A salt wasting syndrome in infancy. Arch Dis Child 1958, 33:252-256.
110. Hanukoglu A., Bistritzer T., Rakover Y., Mandelberg A. Pseudohypoaldosteronism with increased sweat and saliva electrolyte values and frequent lower respiratory tract infections mimicking cystic fibrosis. J Pediatr 1994, 125:752-755.
111. Kerem E., Bistritzer T., Hanukoglu A., Hofmann T., Zhou Z., Bennett W., et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 1999, 341:156-162.
112. Chang S.S., Grunder S., Hanukoglu A., Rosler A., Mathew P.M., Hanukoglu I., et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996, 12:248-253.
113. Strautnieks S.S., Thompson R.J., Gardiner R.M., Chung E. A novel splice-site mutation in the gamma subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families. Nat Genet 1996, 13:248-250.
114. + channel in mice: hyperkalemia and neonatal death associated with a pseudohypoaldosteronism phenotype. Proc Natl Acad Sci USA 1999, 96:1727-1731.
115. Barker P.M., Nguyen M.S., Gatzy J.T., Grubb B., Norman H., Hummler E., et al. Role of gammaENaC subunit in lung liquid clearance and electrolyte balance in newborn mice. Insights into perinatal adaptation and pseudohypoaldosteronism. J Clin Invest 1998, 102:1634-1640.
116. Hummler E., Barker P., Talbot C., Wang Q., Verdumo C., Grubb B., et al. A mouse model for the renal salt-wasting syndrome pseudohypoaldosteronism. Proc Natl Acad Sci USA 1997, 94:11710-11715.
117. Hummler E., Barker P., Gatzy J., Beermann F., Verdumo C., Schmidt A., et al. Early death due to defective neonatal lung liquid clearance in alpha-ENaC-deficient mice. Nat Genet 1996, 12:325-328.
118. Huppmann S., Lankes E., Schnabel D., Buhrer C. Unimpaired postnatal respiratory adaptation in a preterm human infant with a homozygous ENaC-alpha unit loss-of-function mutation. J Perinatol 2011, 31:802-803.
119. Geller D.S., Rodriguez-Soriano J., Vallo Boado A., Schifter S., Bayer M., Chang S.S., et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 1998, 19:279-281.
120. Geller D.S., Zhang J., Zennaro M.C., Vallo-Boado A., Rodriguez-Soriano J., Furu L., et al. Autosomal dominant pseudohypoaldosteronism type 1: mechanisms, evidence for neonatal lethality, and phenotypic expression in adults. J Am Soc Nephrol 2006, 17:1429-1436.
121. Hubert E.L., Teissier R., Fernandes-Rosa F.L., Fay M., Rafestin-Oblin M.E., Jeunemaitre X., et al. Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1. J Am Soc Nephrol 2011, 22:1997-2003.
122. + metabolism. Proc Natl Acad Sci USA 1998, 95:9424-9429.
123. Bleich M., Warth R., Schmidt-Hieber M., Schulz-Baldes A., Hasselblatt P., Fisch D., et al. Rescue of the mineralocorticoid receptor knock-out mouse. Pflugers Arch 1999, 438:245-254.
124. Bartter F.C., Pronove P., Gill J.R., Maccardle R.C. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 1962, 33:811-828.
125. Rodrigues Pereira R., Hasaart T. Hydramnios and observations in Bartter's syndrome. Acta Obstet Gynecol Scand 1982, 61:477-478.
126. Simopoulos A.P. Growth characteristics in patients with Bartter's syndrome. Nephron 1979, 23:130-135.
127. Matsumoto J., Han B.K., Restrepo de Rovetto C., Welch T.R. Hypercalciuric Bartter syndrome: resolution of nephrocalcinosis with indomethacin. AJR Am J Roentgenol 1989, 152:1251-1253.
128. Landau D., Shalev H., Ohaly M., Carmi R. Infantile variant of Bartter syndrome and sensorineural deafness: a new autosomal recessive disorder. Am J Med Genet 1995, 59:454-459.
129. Chaimovitz C., Levi J., Better O.S., Oslander L., Benderli A. Studies on the site of renal salt loss in a patient with Bartter's syndrome. Pediatr Res 1973, 7:89-94.
130. Fichman M.P., Telfer N., Zia P., Speckart P., Golub M., Rude R. Role of prostaglandins in the pathogenesis of Bartter's syndrome. Am J Med 1976, 60:785-797.
131. Verberckmoes R., van Damme B.B., Clement J., Amery A., Michielsen P. Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. Kidney Int 1976, 9:302-307.
132. Gill J.R., Frolich J.C., Bowden R.E., Taylor A.A., Keiser H.R., Seyberth H.W., et al. Bartter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med 1976, 61:43-51.
133. Simon D.B., Karet F.E., Hamdan J.M., DiPietro A., Sanjad S.A., Lifton R.P. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl co-transporter NKCC2. Nat Genet 1996, 13:183-188.
134. Takahashi N., Chernavvsky D.R., Gomez R.A., Igarashi P., Gitelman H.J., Smithies O. Uncompensated polyuria in a mouse model of Bartter's syndrome. Proc Natl Acad Sci USA 2000, 97:5434-5439.
135. + channel, ROMK. Nat Genet 1996, 14:152-156.
136. Hebert S.C. An ATP-regulated, inwardly rectifying potassium channel from rat kidney (ROMK). Kidney Int 1995, 48:1010-1016.
137. Giebisch G. Renal potassium channels: an overview. Kidney Int 1995, 48:1004-1009.
138. Peters M., Jeck N., Reinalter S., Leonhardt A., Tonshoff B., Klaus G.G., et al. Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 2002, 112:183-190.
139. Finer G., Shalev H., Birk O.S., Galron D., Jeck N., Sinai-Treiman L., et al. Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndrome. J Pediatr 2003, 142:318-323.
140. Satlin L.M. Postnatal maturation of potassium transport in rabbit cortical collecting duct. Am J Physiol 1994, 266:F57-F65.
141. + conductance in maturing rabbit principal cell. Am J Physiol 1997, 272:F397-F404.
142. Lorenz J.N., Baird N.R., Judd L.M., Noonan W.T., Andringa A., Doetschman T., et al. Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter's syndrome. J Biol Chem 2002, 277:37871-37880.
143. Simon D.B., Bindra R.S., Mansfield T.A., Nelson-Williams C., Mendonca E., Stone R., et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet 1997, 17:171-178.
144. Vandewalle A., Cluzeaud F., Bens M., Kieferle S., Steinmeyer K., Jentsch T.J. Localization and induction by dehydration of ClC-K chloride channels in the rat kidney. Am J Physiol 1997, 272:F678-F688.
145. Adachi S., Uchida S., Ito H., Hata M., Hiroe M., Marumo F., et al. Two isoforms of a chloride channel predominantly expressed in thick ascending limb of Henle's loop and collecting ducts of rat kidney. J Biol Chem 1994, 269:17677-17683.
146. Kieferle S., Fong P., Bens M., Vandewalle A., Jentsch T.J. Two highly homologous members of the ClC chloride channel family in both rat and human kidney. Proc Natl Acad Sci USA 1994, 91:6943-6947.
147. Jeck N., Konrad M., Peters M., Weber S., Bonzel K.E., Seyberth H.W. Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. Pediatr Res 2000, 48:754-758.
148. Brennan T.M., Landau D., Shalev H., Lamb F., Schutte B.C., Walder R.Y., et al. Linkage of infantile Bartter syndrome with sensorineural deafness to chromosome. Am J Hum Genet 1998, 62:355-361.
149. Birkenhager R., Otto E., Schurmann M.J., Vollmer M., Ruf E.M., Maier-Lutz I., et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 2001, 29:310-314.
150. + secretion. Nature 2001, 414:558-561.
151. Schlingmann K.P., Konrad M., Jeck N., Waldegger P., Reinalter S.C., Holder M., et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med 2004, 350:1314-1319.
152. Nozu K., Inagaki T., Fu X.J., Nozu Y., Kaito H., Kanda K., et al. Molecular analysis of digenic inheritance in Bartter syndrome with sensorineural deafness. J Med Genet 2008, 45:182-186.
153. Matsumura Y., Uchida S., Kondo Y., Miyazaki H., Ko S.B., Hayama A., et al. Overt nephrogenic diabetes insipidus in mice lacking the CLC-K1 chloride channel. Nat Genet 1999, 21:95-98.
154. - channels: mechanism underlying deafness in Bartter syndrome IV. EMBO J 2008, 27:2907-2917.
155. Pearce S.H., Williamson C., Kifor O., Bai M., Coulthard M.G., Davies M., et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 1996, 335:1115-1122.
156. Vargas-Poussou R., Huang C., Hulin P., Houillier P., Jeunemaitre X., Paillard M., et al. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 2002, 13:2259-2266.
157. Watanabe S., Fukumoto S., Chang H., Takeuchi Y., Hasegawa Y., Okazaki R., et al. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 2002, 360:692-694.
158. 2+)-sensing receptor in divalent mineral ion homeostasis. J Exp Biol 1997, 200:295-302.
159. Seyberth H.W., Koniger S.J., Rascher W., Kuhl P.G., Schweer H. Role of prostaglandins in hyperprostaglandin E syndrome and in selected renal tubular disorders. Pediatr Nephrol 1987, 1:491-497.
160. Rodriguez-Soriano J., Vallo A., Perez de Nanclares G., Bilbao J.R., Castano L. A founder mutation in the CLCNKB gene causes bartter syndrome type III in Spain. Pediatr Nephrol 2005, 20:891-896.
161. Reinalter S.C., Jeck N., Brochhausen C., Watzer B., Nusing R.M., Seyberth H.W., et al. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 2002, 62:253-260.
162. Chaudhuri A., Salvatierra O., Alexander S.R., Sarwal M.M. Option of pre-emptive nephrectomy and renal transplantation for Bartter's syndrome. Pediatr Transplant 2006, 10:266-270.
163. Gitelman H.J., Graham J.B., Welt L.G. A new familial disorder
164. Bettinelli A., Bianchetti M.G., Girardin E., Caringella A., Cecconi M., Appiani A.C., et al. Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: bartter and Gitelman syndromes. J Pediatr 1992, 120:38-43.
165. Sutton R.A., Mavichak V., Halabe A., Wilkins G.E. Bartter's syndrome: evidence suggesting a distal tubular defect in a hypocalciuric variant of the syndrome. Miner Electrolyte Metab 1992, 18:43-51.
166. Gamba G., Miyanoshita A., Lombardi M., Lytton J., Lee W.S., Hediger M.A., et al. Molecular cloning, primary structure, and characterization of two members of the mammalian electroneutral sodium-(potassium)-chloride co-transporter family expressed in kidney. J Biol Chem 1994, 269:17713-17722.
167. Gamba G., Saltzberg S.N., Lombardi M., Miyanoshita A., Lytton J., Hediger M.A., et al. Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride co-transporter. Proc Natl Acad Sci USA 1993, 90:2749-2753.
168. Simon D.B., Nelson-Williams C., Bia M.J., Ellison D., Karet F.E., Molina A.M., et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl co-transporter. Nat Genet 1996, 12:24-30.
169. Ji W., Foo J.N., O'Roak B.J., Zhao H., Larson M.G., Simon D.B., et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008, 40:592-599.
170. Cruz D.N., Shaer A.J., Bia M.J., Lifton R.P., Simon D.B. Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 2001, 59:710-717.
171. 2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 2005, 115:1651-1658.
172. Schlingmann K.P., Weber S., Peters M., Niemann Nejsum L., Vitzthum H., Klingel K., et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 2002, 31:166-170.
173. - co-transporter of the distal convoluted tubule. J Biol Chem 1998, 273:29150-29155.
174. Loffing J., Loffing-Cueni D., Hegyi I., Kaplan M.R., Hebert S.C., Le Hir M., et al. Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int 1996, 50:1180-1190.
175. Morris R.G., Hoorn E.J., Knepper M.A. Hypokalemia in a mouse model of Gitelman's syndrome. Am J Physiol Renal Physiol 2006, 290:F1416-F1420.
176. Scholl U.I., Choi M., Liu T., Ramaekers V.T., Hausler M.G., Grimmer J., et al. Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. Proc Natl Acad Sci USA 2009, 106:5842-5847.
177. Bockenhauer D., Feather S., Stanescu H.C., Bandulik S., Zdebik A.A., Reichold M., et al. Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med 2009, 360:1960-1970.
178. Djukic B., Casper K.B., Philpot B.D., Chin L.S., McCarthy K.D. Conditional knock-out of Kir4.1 leads to glial membrane depolarization, inhibition of potassium and glutamate uptake, and enhanced short-term synaptic potentiation. J Neurosci 2007, 27:11354-11365.
179. Kofuji P., Ceelen P., Zahs K.R., Surbeck L.W., Lester H.A., Newman E.A. Genetic inactivation of an inwardly rectifying potassium channel (Kir4.1 subunit) in mice: phenotypic impact in retina. J Neurosci 2000, 20:5733-5740.
180. Neusch C., Rozengurt N., Jacobs R.E., Lester H.A., Kofuji P. Kir4.1 potassium channel subunit is crucial for oligodendrocyte development and in vivo myelination. J Neurosci 2001, 21:5429-5438.
181. + buffering to cell differentiation. J Neurochem 2008, 107:589-601.
182. Chever O., Djukic B., McCarthy K.D., Amzica F. Implication of Kir4.1 channel in excess potassium clearance: an in vivo study on anesthetized glial-conditional Kir4.1 knock-out mice. J Neurosci 2010, 30:15769-15777.
183. Rozengurt N., Lopez I., Chiu C.S., Kofuji P., Lester H.A., Neusch C. Time course of inner ear degeneration and deafness in mice lacking the Kir4.1 potassium channel subunit. Hear Res 2003, 177:71-80.
184. Koefoed-Johnsen V., Ussing H.H. The nature of the frog skin potential. Acta Physiol Scand 1958, 42:298-308.
185. Reichold M., Zdebik A.A., Lieberer E., Rapedius M., Schmidt K., Bandulik S., et al. KCNJ10 gene mutations causing EAST syndrome (epilepsy, ataxia, sensorineural deafness, and tubulopathy) disrupt channel function. Proc Natl Acad Sci USA 2010, 107:14490-14495.
186. Freudenthal B., Kulaveerasingam D., Lingappa L., Shah M.A., Brueton L., Wassmer E., et al. KCNJ10 mutations disrupt function in patients with EAST syndrome. Nephron Physiol 2011, 119:40-48.
187. Thompson D.A., Feather S., Stanescu H.C., Freudenthal B., Zdebik A.A., Warth R., et al. Altered electroretinograms in patients with KCNJ10 mutations and EAST syndrome. J Physiol 2011, 589:1681-1689.
188. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
189. Global health risks - mortality and burden of disease attributable to selected major risks 2009, WHO, WHO, Geneva.
190. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the jnc 7 report. Jama 2003, 289:2560-2572.
191. Feinleib M., Garrison R.J., Fabsitz R., Christian J.C., Hrubec Z., Borhani N.O., et al. The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results. Am J Epidemiol 1977, 106:284-285.
192. Longini I.M., Higgins M.W., Hinton P.C., Moll P.P., Keller J.B. Environmental and genetic sources of familial aggregation of blood pressure in Tecumseh, Michigan. Am J Epidemiol 1984, 120:131-144.
193. Kupper N., Willemsen G., Riese H., Posthuma D., Boomsma D.I., de Geus E.J. Heritability of daytime ambulatory blood pressure in an extended twin design. Hypertension 2005, 45:80-85.
194. Newton-Cheh C., Johnson T., Gateva V., Tobin M.D., Bochud M., Coin L., et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009, 41:666-676.
195. Levy D., Ehret G.B., Rice K., Verwoert G.C., Launer L.J., Dehghan A., et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009, 41:677-687.
196. Tennessen J.A., Bigham A.W., O'Connor T.D., Fu W., Kenny E.E., Gravel S., et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 2012, 337:64-69.
197. Sacks F.M., Svetkey L.P., Vollmer W.M., Appel L.J., Bray G.A., Harsha D., et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (dash) diet. Dash-sodium collaborative research group. N Engl J Med 2001, 344:3-10.
198. Cappuccio F.P., MacGregor G.A. Does potassium supplementation lower blood pressure? A meta-analysis of published trials. J Hypertens 1991, 9:465-473.
199. Whelton P.K., He J., Cutler J.A., Brancati F.L., Appel L.J., Follmann D., et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. Jama 1997, 277:1624-1632.
200. Geleijnse J.M., Kok F.J., Grobbee D.E. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens 2003, 17:471-480.
201. He F.J., Marciniak M., Visagie E., Markandu N.D., Anand V., Dalton R.N., et al. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertension 2009, 54:482-488.
202. Bibbins-Domingo K., Chertow G.M., Coxson P.G., Moran A., Lightwood J.M., Pletcher M.J., et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 2010, 362:590-599.
203. McGuire S Institute of Medicine. Strategies to reduce sodium intake in the United States. Adv Nutr 2010, 1. The National Academies Press, Washington, DC, 49-50.
204. Kayikcioglu M., Tumuklu M., Ozkahya M., Ozdogan O., Asci G., Duman S., et al. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol Dial Transplant 2009, 24:956-962.
205. Chazot C., Charra B., Laurent G., Didier C., Vo Van C., Terrat J.C., et al. Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant 1995, 10:831-837.
206. Culleton B.F., Walsh M., Klarenbach S.W., Mortis G., Scott-Douglas N., Quinn R.R., et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. Jama 2007, 298:1291-1299.
207. Cruz D.N., Simon D.B., Nelson-Williams C., Farhi A., Finberg K., Burleson L., et al. Mutations in the Na-Cl co-transporter reduce blood pressure in humans. Hypertension 2001, 37:1458-1464.